Cell-based immunotherapies like Chimeric Antigen Receptor (CAR)-T cell therapy have been transforming the treatment of hematologic malignancies for more than a decade. Several groundbreaking studies (1) have led to a growing interest in applying these cell-based therapies to other T and B cell-mediated diseases.  One emerging application of CARs is…